BDRX (Biodexa Pharmaceuticals) ROCE %: -39.48% (As of Dec. 2025)


BDRX Biodexa Pharmaceuticals PLC BDRX
45 GF Score
Price $2.55
GF Value $2.26
Valuation Modestly Overvalued
View Full Analysis

What is Biodexa Pharmaceuticals ROCE %?

Biodexa Pharmaceuticals BDRX -2.30% 45 ROCE % is -39.48% as of Dec. 2025. GuruFocus rates BDRX with a GF Score™ of 45/100 and a GF Value™ of $2.26 (Modestly Overvalued).

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Biodexa Pharmaceuticals's annualized ROCE % for the quarter that ended in Dec. 2025 was -39.48%.

Biodexa Pharmaceuticals  (NAS:BDRX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Biodexa Pharmaceuticals ROCE % Related Terms

Biodexa Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Biodexa Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biodexa Pharmaceuticals ROCE % Chart

Biodexa Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -67.45 -107.36 -175.95 -78.96 -58.91

Biodexa Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -135.76 -87.69 -47.88 -71.62 -39.48
BDRX
45GF Score
Biodexa Pharmaceuticals PLC BDRX
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biodexa Pharmaceuticals ROCE % Calculation

Biodexa Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-8.38/( ( (18.685 - 6.364) + (24.336 - 8.205) )/ 2 )
=-8.38/( (12.321+16.131)/ 2 )
=-8.38/14.226
=-58.91 %

Biodexa Pharmaceuticals's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-6.49/( ( (20.114 - 3.364) + (24.336 - 8.205) )/ 2 )
=-6.49/( ( 16.75 + 16.131 )/ 2 )
=-6.49/16.4405
=-39.48 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -39.48% mean?
Biodexa Pharmaceuticals (BDRX) has a ROCE % of -39.48% as of Dec. 2025.
Is Biodexa Pharmaceuticals' ROCE % too high?
Biodexa Pharmaceuticals' current ROCE % is -39.48%. Overall, Biodexa Pharmaceuticals has a GF Score™ of 45/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biodexa Pharmaceuticals' ROCE % compare to CASIF and OGEN?
Biodexa Pharmaceuticals' ROCE % of -39.48% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Biodexa Pharmaceuticals's current ROCE % is -39.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biodexa Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Biodexa Pharmaceuticals (BDRX) is currently considered Modestly Overvalued. The stock's GF Value™ is $2.26, compared to a current price of $2.55 — trading 12.8% above its estimated fair value. The current ROCE % is -39.48%. Biodexa Pharmaceuticals' overall GF Score™ is 45/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Biodexa Pharmaceuticals (BDRX), the current ROCE % is -39.48% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biodexa Pharmaceuticals (BDRX) Overvalued in 2026?

Based on GuruFocus' analysis, Biodexa Pharmaceuticals stock appears to be overvalued. The current stock price of $2.55 is trading 12.8% above its estimated GF Value™ of $2.26. GuruFocus considers Biodexa Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for BDRX:

  • ROCE %: -39.48%
  • GF Value™: $2.26 vs. price of $2.55 (12.8% above fair value)
  • GF Score™: 45/100

No single metric tells the full story. See the BDRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biodexa Pharmaceuticals Business Description

Address 1 Caspian Point, Caspian Way, Cardiff, GBR, CF10 4DQ
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
45GF Score

Get the complete analysis for BDRX

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.55
Price
$2.26
GF Value